GET DAILY SIGNALSWhy Is Replimune Group (REPL) Stock Up +18.7% Today?
Key Takeaways
- Shares surged roughly 18.7% to $15.49, up from the previous session's close of $13.05, as investors rewarded an earnings beat and early launch momentum.
- Primary catalyst: REPL reported a narrower-than-expected fiscal second-quarter loss of $0.54 per share, topping consensus estimates.
- Secondary driver: Management detailed encouraging early traction for TUDRIQEV, its newly launched advanced-melanoma therapy, with more than 70% of target accounts already engaged.
- Broader context: The move reflects renewed biotech appetite for commercial-stage oncology launches, even amid a mixed tape for the broader market.
- What to watch next: Initial product revenue in the fiscal third quarter, reimbursement and formulary updates, and progress on confirmatory clinical trials.
- For more on Price Targets, Earnings, and Forecast for REPL, explore these dedicated pages.
- Discover the strongest-performing strategies under current market conditions with Tickeron's Trending AI Robots.
Opening Summary
Replimune Group, Inc. (REPL), a Woburn, Massachusetts-based commercial-stage biotechnology company developing oncolytic immunotherapies, saw its stock rally sharply on Wednesday after reporting fiscal second-quarter results. The shares climbed roughly 18.7% to $15.49, up $2.44 from the prior session's close of $13.05, as markets reacted to a stronger-than-expected bottom line and early signs of commercial uptake for the company's lead product.
Earnings Beat Fuels the Rally
The clearest catalyst was the company's earnings report. For its fiscal second quarter ended September 30, 2026, REPL posted a net loss of $57.1 million, or $0.54 per share, narrower than the consensus estimate of roughly $0.75 to $0.78 per share. Research and development expense fell to $34.4 million from $57.9 million a year earlier, while selling, general, and administrative expense declined to $21.9 million from $26.4 million. The bottom-line improvement reflected a leaner cost structure as the company transitions from clinical-stage to commercial operations.
TUDRIQEV Launch Shows Early Traction
Beyond the headline numbers, investors focused on the commercial launch of TUDRIQEV (vusolimogene oderparepvec), the company's oncolytic immunotherapy approved in August for advanced melanoma. Management reported that more than 70% of its initial 200 target accounts have been engaged, roughly 20 institutions have added the therapy to their formularies, and more than 15 had written prescriptions within the first 20 business days. TUDRIQEV was first delivered to patients on October 6, and the company said it has more than a year of inventory on hand from its in-house manufacturing facility.
Financial Position and Launch Momentum
The company ended the quarter with $307.8 million in cash and cash equivalents, which management expects to fund operations for more than 12 months while supporting the launch, the IGNYTE-3 confirmatory study, and the REVEAL uveal melanoma trial. Although REPL recorded no product revenue in the quarter because commercial shipments began in October, the company anticipates reporting initial product sales in the fiscal third quarter. Management expects the number of accounts initiating patients could double by year-end.
Market Context and Trading Activity
The stock's move reflects a pronounced market reaction to an earnings-driven catalyst in the biotechnology sector. Shares broke decisively above recent trading levels, and the rally pushed the stock toward the upper end of its 52-week range of $1.50 to $16.33. The move is consistent with a pattern seen across clinical and early commercial-stage oncology names, where investors have rewarded concrete launch data over earnings-per-share alone. With seven of eight covering analysts rating the stock a buy and a mean price target above recent levels, the positive momentum aligned with a broadly constructive sentiment toward newly approved cancer therapies.
What Comes Next for REPL
Looking ahead, the key focus will be whether early launch indicators translate into visible revenue growth. Investors will monitor formulary additions, reimbursement negotiations, and the permanent J-code expected by April 2027, as well as progress on the IGNYTE-3 Phase 3 confirmatory trial. Competitive dynamics remain a factor, with Iovance Biotherapeutics' Amtagvi representing the other approved option for advanced melanoma patients who progress after PD-1 therapy. Risks include execution challenges in scaling the commercial launch and the inherent uncertainty of confirmatory trial outcomes.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the strongest performers under current market conditions are highlighted in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a range of approaches to evaluate. Explore the Trending AI Robots page to discover which automated strategies are leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
REPL's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for REPL turned positive on October 26, 2026. Looking at past instances where REPL's MACD turned positive, the stock continued to rise in 46 of 50 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where REPL's RSI Oscillator exited the oversold zone, 36 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 59 cases where REPL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on REPL as a result. In 64 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +13.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 184 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
REPL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
REPL moved below its 50-day moving average on October 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for REPL crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for REPL entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.639) is normal, around the industry mean (2.974). P/E Ratio (-4.143) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of oncolytic immunotherapies
Industry Biotechnology
Advertisement